According to Actoverco Pharmaceutical Group’s Public Relations Office, over 750 national and international speakers and panelists participated in more than 150 sessions, presenting the latest advancements and research in various fields of cardiology and cardiovascular medicine.

Actoverco, a leading pharmaceutical manufacturer with over five decades of expertise, participated in the event’s accompanying exhibition. The company showcased its extensive range of cardiovascular products, emphasizing its commitment to innovation and therapeutic excellence.

In his opening remarks, Dr. Fereydoun Noohi, President of the 10th Congress, emphasized that access to cardiovascular healthcare in Iran has reached a satisfactory level. However, he warned of the growing prevalence of cardiovascular diseases, which remain the leading cause of mortality both globally and domestically. “According to international data, deaths caused by cardiovascular diseases have risen from 13 million in 2004 to over 21 million in 2024, now accounting for approximately 31% of global deaths,” he stated.

Dr. Noohi highlighted alarming health trends in Iran: about 25% of the population is obese, 32% lack adequate physical activity, nearly 60% are overweight, and metabolic syndrome affects 25% of women and 17% of men. Approximately 10% of Iranians are also living with diabetes.

On a more positive note, he pointed to significant advancements in the country’s cardiac infrastructure. The number of active angiography devices has grown from 79 in 2004 to 659 in 2024, and the number of cardiac surgery centers has increased from 41 to over 100. Similarly, cardiology training centers have expanded from 8 to 31, with over 220 cardiac surgeons currently practicing in Iran.

Despite these advances, Dr. Noohi stressed the need for continued investment in underserved regions. “Fortunately, advanced treatment methods are now available in Iran,” he noted, citing Shaheed Rajaie Heart Center’s 2023 statistics, which include more than 1,800 coronary artery bypass surgeries, 10,000 angiographies, 771 primary percutaneous coronary interventions (PPCI), 367 transcatheter aortic valve implantations (TAVI), and 488 electrophysiology studies (EPS).

He concluded by emphasizing the importance of structured and continuous preventive strategies, noting that over 247,000 specialized cardiovascular services were registered last year, significantly reducing mortality and disability from heart disease.

Actoverco’s Cardiovascular Product Portfolio

At the congress, Actoverco highlighted its extensive range of cardiovascular treatments, including:

• Lepixa® (Apixaban): A direct oral anticoagulant (DOAC) that inhibits factor Xa, reducing the tendency of blood to form clots. 

• Ticora® (Ticagrelor): An antiplatelet agent used to lower the chance of heart attack, stroke, and death in patients with acute coronary syndrome or a history of myocardial infarction. 

• Zylt® (Clopidogrel): An antiplatelet medication produced under license from KRKA, Slovenia, used to prevent blood clots.

• Rytcard® (Flecainide Acetate): Used to treat certain types of abnormal heartbeats (arrhythmias). 

• Clotover® (Rivaroxaban): A DOAC that inhibits factor Xa, used to treat and prevent blood clots and reduce the risk of heart attack and stroke. 

• Bitval® (Sacubitril/Valsartan): A combination therapy for managing heart failure, reducing the risk of death and hospitalization. 

• Croszet® (Ezetimibe/Rosuvastatin): A lipid-lowering agent that combines cholesterol absorption inhibition and statin therapy to treat hyperlipidemia. 

• Rosurexin® (Rosuvastatin): An HMG-CoA reductase inhibitor (statin) used to lower bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). 

• Telmyc® (Telmisartan): An angiotensin II receptor blocker (ARB) used to treat high blood pressure.

• AmloTelmyc® (Telmisartan/Amlodipine): A combination of an ARB and a calcium channel blocker used to treat high blood pressure.

• Telmyc-H® (Telmisartan/Hydrochlorothiazide): A combination of an ARB and a diuretic used to treat high blood pressure. 

• Valosep® (Amlodipine/Valsartan): A combination of a calcium channel blocker and an ARB used to treat high blood pressure.

• Metazero® (Metoprolol Succinate): A beta-blocker manufactured under license from KRKA, Slovenia, used to treat angina and high blood pressure.

• Eprinsa® (Eplerenone): A mineralocorticoid receptor antagonist used to treat high blood pressure and improve heart function after a heart attack. 

• Irbesal® (Irbesartan): An ARB used to treat high blood pressure and protect kidney function in patients with diabetes. 

• Raliza® (Ranolazine): An antianginal medication used for chronic chest pain relief.

Actoverco continues to play a vital role in Iran’s pharmaceutical landscape, offering more than 300 products across 15 therapeutic areas, with a strong focus on cardiovascular health. Its participation in this high-profile congress reaffirmed its position as a key player in promoting heart health and advancing clinical care in Iran.